Literature DB >> 28063129

Rates of Nonsteroidal Anti-Inflammatory Drug Use in Patients with Established Cardiovascular Disease: A Retrospective, Cross-Sectional Study from NHANES 2009-2010.

Gregory Castelli1,2, Ashley Petrone3, Jun Xiang2, Carl Shrader2, Dana King2.   

Abstract

PURPOSE: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain, inflammation, and fever in the USA. Unfortunately, NSAIDs have been associated with an increased risk of adverse cardiovascular events, especially among NSAID users with established cardiovascular disease (CVD). In 2005, the Food and Drug Administration (FDA) released an initial warning regarding NSAID use and CVD risk, and recently, in July 2015, released an updated statement strengthening this initial warning. The purpose of this study is to evaluate the rates of NSAID use among patients with CVD following the 2005 FDA warning regarding NSAID use and increased CVD risk.
METHODS: This was a retrospective, cross-sectional study of participants from the National Health and Nutrition Examination Survey, 2009-2010. Participants' CVD status was determined by self-reported diagnosis. Current use of over the counter (OTC) NSAIDs was defined by self-reported use of ibuprofen or naproxen, and we identified the current use of prescription NSAIDs in the database of prescription medication.
RESULTS: Respondents with CVD were 2.1 times more likely to use OTC NSAIDs or prescription NSAIDs than respondents without CVD. Among CVD patients, respondents with angina and myocardial infarction were 60% more likely to use any form of NSAID, and respondents with congestive heart failure were less likely to use any form of NSAID than those with other forms of CVD.
CONCLUSIONS: Our results indicate that there is still a large proportion of CVD patients using NSAIDs. It is now crucial to determine the reasons why prescribers are still prescribing NSAIDs despite the FDA warning.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28063129      PMCID: PMC5513157          DOI: 10.1007/s40256-016-0212-1

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  23 in total

1.  Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Ryne Paulose-Ram; Rosemarie Hirsch; Charles Dillon; Katalin Losonczy; Michael Cooper; Yechiam Ostchega
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003-06       Impact factor: 2.890

2.  Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.

Authors:  Søren P Johnsen; Heidi Larsson; Robert E Tarone; Joseph K McLaughlin; Bente Nørgård; Søren Friis; Henrik T Sørensen
Journal:  Arch Intern Med       Date:  2005-05-09

3.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Authors:  F Catella-Lawson; M P Reilly; S C Kapoor; A J Cucchiara; S DeMarco; B Tournier; S N Vyas; G A FitzGerald
Journal:  N Engl J Med       Date:  2001-12-20       Impact factor: 91.245

4.  Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study.

Authors:  Morten Lamberts; Gregory Y H Lip; Morten Lock Hansen; Jesper Lindhardsen; Jonas Bjerring Olesen; Jakob Raunsø; Anne-Marie Schjerning Olsen; Per Kragh Andersen; Thomas Alexander Gerds; Emil L Fosbøl; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Ann Intern Med       Date:  2014-11-18       Impact factor: 25.391

5.  Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.

Authors:  Marisa Battistella; Muhammad M Mamdami; David N Juurlink; Linda Rabeneck; Andreas Laupacis
Journal:  Arch Intern Med       Date:  2005-01-24

6.  Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction.

Authors:  Anne-Marie Schjerning Olsen; Gunnar H Gislason; Patricia McGettigan; Emil Fosbøl; Rikke Sørensen; Morten Lock Hansen; Lars Køber; Christian Torp-Pedersen; Morten Lamberts
Journal:  JAMA       Date:  2015-02-24       Impact factor: 56.272

7.  Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure.

Authors:  Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrom; Tina K Schramm; Morten L Hansen; Emil L Fosbøl; Rikke Sørensen; Fredrik Folke; Pernille Buch; Niels Gadsbøll; Søren Rasmussen; Henrik E Poulsen; Lars Køber; Mette Madsen; Christian Torp-Pedersen
Journal:  Arch Intern Med       Date:  2009-01-26

8.  Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.

Authors:  Mendel D M Haag; Michiel J Bos; Albert Hofman; Peter J Koudstaal; Monique M B Breteler; Bruno H C Stricker
Journal:  Arch Intern Med       Date:  2008-06-09

Review 9.  Hepatotoxicity of nonsteroidal anti-inflammatory drugs.

Authors:  M Rabinovitz; D H Van Thiel
Journal:  Am J Gastroenterol       Date:  1992-12       Impact factor: 10.864

10.  Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.

Authors:  M E Farkouh; J D Greenberg; R V Jeger; K Ramanathan; F W A Verheugt; J H Chesebro; H Kirshner; J S Hochman; C L Lay; S Ruland; B Mellein; P T Matchaba; V Fuster; S B Abramson
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

View more
  4 in total

1.  Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease.

Authors:  Zachary Bouck; Graham C Mecredy; Noah M Ivers; Moumita Barua; Danielle Martin; Peter C Austin; Joshua Tepper; R Sacha Bhatia
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873

Review 2.  Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.

Authors:  Zoltan Varga; Syed Rafay Ali Sabzwari; Veronika Vargova
Journal:  Cureus       Date:  2017-04-08

3.  Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact.

Authors:  Mirjam Hempenius; Rolf H H Groenwold; Anthonius de Boer; Olaf H Klungel; Helga Gardarsdottir
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-09-07       Impact factor: 2.732

4.  The difference in knowledge and attitudes of using mobile health applications between actual user and non-user among adults aged 50 and older.

Authors:  Mangyeong Lee; Danbee Kang; Junghee Yoon; Sungkeun Shim; Im-Ryung Kim; Dongryul Oh; Soo-Yong Shin; Bradford W Hesse; Juhee Cho
Journal:  PLoS One       Date:  2020-10-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.